Non-Medical Switches of Biosimilar in Psoriasis Treatment Appears Safe
Christoffer Willy Schwarz presented a real-world study at EADV 2024 on non-medical switches between adalimumab products in psoriasis patients. Among 180 patients, the risk of discontinuation within six months was 0-8%, with the highest rate (8%) linked to switching from the reference drug to a biosimilar. The results suggest switching is generally safe, although the study is limited by its size and scope.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in